Paper-COVID - Platform for High-throughput SARS-CoV-2 Screening and Contact Tracing

摘要 目前，大多数COVID-19的诊断检测都是通过当地对那些 出现症状后进行集中实验室检测-3-4天内返回结果。这一点现在得到了补充 通过几个即时护理（Point-of-Care，简称POS）系统，这些系统可以在现场执行相同的测试，更快地返回结果， 但吞吐量低得多。为了使美国经济的许多要素恢复到更接近正常的功能， 作为国际航空旅行，大规模的雇主，和校园为基础的高等院校，将需要我们 从诊断性检测转向大规模、分布式和重复筛查无症状（或预 症状）个体。传统的集中式测试的时间长度和相对较低的 现有的RFID系统的吞吐量将使这成为一个挑战。 在这里，我们建议开发Paper-COVID -一个模块化平台，结合临床验证的LAMP检测 （已获得FDA EUA批准），并采用基于移动的手机的纸张测试平台， 无症状SARS-CoV-2的通量筛查，并促进自动化接触者追踪。我们的目标是 努力验证一种新的样品处理技术，将以前开发的LAMP检测方法移植到纸上， 的格式，构建了三个模块化的原型系统，并验证它对临床样本从纽约 市

Abstract At present, most of the diagnostic testing for COVID-19 has been done through local sampling of those who are symptomatic followed by centralized laboratory testing – returning results in 3-4 days. This is now supplemented by several point-of-care (PoC) systems who can perform the same test on site, returning the result much quicker, but at much lower throughput. To return many elements of the US economy to closer to normal function, such as international air travel, large-scale employers, and campus-based institutes of higher learning, will require us to shift from diagnostic testing to large scale, distributed, and repeated screening of asymptomatic (or pre- symptomatic) individuals. The length of time-to-result for traditional centralized testing and the relatively low throughput of existing PoC systems will make this a challenge. Here we propose to develop Paper-COVID – a modular platform that combines a clinically validated LAMP assay (already with FDA EUA approval) with a mobile phone based paper testing platform that enables much higher throughput screening for asymptomatic SARS-CoV-2 and facilitates automated contact tracing. The goal for this effort is to validate a novel sample processing technique, port the previously developed LAMP assay to a paper- based format, construct three modular prototype systems, and validate it on clinical samples from New York City.